peptidylprolyl isomerase A pseudogene 6Genealiases: PPIAP12 · PPIP2
Q-omics provides the consensus-scored PPIAP6 profile across patient tissues and cancer cell-line models. PPIAP6 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPIAP6 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, PPIAP6 RNA expression shows 12,730 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where PPIAP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP6 survival associations across molecular data types. PPIAP6 RNA expression shows survival associations in the most cancer types (29). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP6 RNA expression–survival associations across cancer types. High PPIAP6 expression shows unfavorable associations in UVM, LIHC, BRCA, ACC and KICH, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPIAP6 RNA expression.
This table summarizes PPIAP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP6 shows higher tumor expression in LIHC, KIRP, HNSC, BRCA, KIRC and COAD. The LIHC box plot shows higher PPIAP6 RNA expression in tumor versus normal tissue (log2 FC = +0.344, t-test p < 0.001).
This table shows molecular features associated with PPIAP6 in patient tissues and cancer cell lines. In patient samples, PPIAP6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
